All articles tagged with #osteoarthritis
Stanford researchers discovered that blocking the aging protein 15-PGDH can restore cartilage in mice and human tissue. This approach reverses age-related joint damage and prevents arthritis after injury, potentially replacing joint surgeries with a simple drug.
A long-term analysis of a Russian trial indicates that low-dose radiation therapy may not only relieve pain but also slow structural deterioration in early-stage knee osteoarthritis, potentially reducing disability and the need for knee replacements.
Researchers have detected elemental sulfur in mammalian cells for the first time, revealing that human and mouse cells actively produce S8 rings to limit oxidative damage. This finding challenges previous assumptions that only bacteria, plants, and fungi utilize elemental sulfur, suggesting a new metabolic pathway in mammals.
A comprehensive study in Nature maps how human-specific genetic changes in gene-regulatory regions led to a significant reduction in glycosaminoglycan (GAG) content in human joints. By analyzing over 560,000 DNA variants, researchers found that humans have approximately 62% less GAG in their cartilage compared to non-human apes. This evolutionary shift, which shows signs of natural selection, likely contributed to the development of human skeletal morphology but also explains why humans are far more susceptible to degenerative joint diseases like osteoarthritis than other great apes.
Researchers at the University at Buffalo developed an injectable hydrogel that transitions to a lubricating semisolid depot inside the joint, releasing drug-loaded nanocarriers over weeks to extend treatment duration for osteoarthritis while potentially reducing injections and limiting systemic exposure.
Yale researchers repurposed lacosamide, an FDA-approved epilepsy drug, with a collagen II hydrogel delivered directly into the knee to simultaneously relieve pain and reverse cartilage damage in osteoarthritis. They show Nav1.7 drives both pain and cartilage breakdown in chondrocytes, and, at a precise low dose, lacosamide boosts cartilage-building proteins while triggering protective signals (HSP70 and midkine). The hydrogel enables weeks-long, localized drug release, outperforming daily oral dosing in preclinical tests, suggesting a faster path to human trials since the drug is already approved.
Researchers developed a silk-protein–gelatine 3D scaffold chemically modified to block bone morphogenetic protein (BMP) signaling while enabling WNT/β-catenin pathways. Implanted into rat knee cartilage defects, the scaffold supported new cartilage formation expressing cartilage-specific collagen, with minimal inflammation and a tissue structure closely resembling natural cartilage, offering a potential approach for osteoarthritis treatment.
Stanford researchers identify the enzyme 15-PGDH as a key aging brake on cartilage repair. In mice, inhibiting 15-PGDH thickened worn cartilage and prevented arthritis after joint injury; human cartilage samples showed similar improvements, suggesting a potential new therapy for aging- and injury-related osteoarthritis. The work is part of broader ARPA-H/NITRO efforts with clinical trials planned, and does not rely on stem cells, instead reactivating existing cartilage cells.
Using Japanese claims data (2015–2024), new denosumab users had a 16% lower 3-year risk of developing osteoarthritis vs new oral bisphosphonate users (relative risk 0.84; 95% CI 0.73–0.89), especially for knee and hip OA. The benefit was not significant for those who switched from bisphosphonates to denosumab. Given the observational design and potential confounding, findings should be interpreted with caution and require clinically validated OA outcomes.
South Korean researchers identify SHP (NR0B2) as a natural cartilage protector; in animal models, restoring SHP reduced joint damage and pain, and SHP gene delivery into damaged joints yielded lasting benefits, suggesting a potential approach to slow or prevent osteoarthritis—though human trials are needed and results are preclinical.
Carly Simon revealed she has Parkinson’s disease, whose early signs began with arthritis in her knees and a hip that required joint replacements; after a Mayo Clinic evaluation she was diagnosed, highlighting research showing a link between arthritis (especially osteoarthritis) and Parkinson’s, and noting apathy as a common non-motor symptom; she’s started treatment and continues to work on music, including a new album.
Stanford researchers report in mice that blocking a specific enzyme can restore cartilage thickness in aging knees, hinting that future pills or injections could repair osteoarthritis and reduce the need for knee or hip replacements. The approach reprograms cells to a younger state by inhibiting an enzyme; the same drug has completed phase 1 safety testing in humans and is heading to phase 2b trials for sarcopenia, signaling broader medical potential.
A 10-year randomized study in the New England Journal of Medicine found that arthroscopic shaving of degenerative meniscal tears provides little to no benefit compared with sham surgery or physical therapy and may worsen pain and accelerate osteoarthritis, sometimes leading to more surgery such as knee replacement; the findings echo decades of evidence against routine knee arthroscopy and have helped reduce the procedure in many countries, though treatment varies and acute injuries may still warrant different care.
UC Boulder researchers report that a single, slow-release injection into damaged joints reversed osteoarthritis in animal models within four to eight weeks, with encouraging early tests on human cells; phase II safety/toxicity studies are planned ahead of potential human trials, though peer review is pending.
Colorado researchers report two regenerative therapies that reversed osteoarthritis signs in animals within 4–8 weeks: an injectable drug-delivery system using a repurposed FDA-approved drug and a biomaterial that recruits body-progenitor cells to repair cartilage. Backed by ARPA-H’s NITRO program with up to $33.5 million, the team has moved from phase one to phase two, with potential human trials in about 18 months and plans for commercial development through Renovare Therapeutics.